<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364089</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2012/34</org_study_id>
    <nct_id>NCT02364089</nct_id>
  </id_info>
  <brief_title>Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas</brief_title>
  <acronym>CHIRACIC</acronym>
  <official_title>Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective is to evaluate the consequences of surgical removal of SCSI on&#xD;
      hypertension and cardiovascular risk factors in order to determine on an evidence-based basis&#xD;
      if surgical excision of SCSI is preferable to an intensive medical regimen in patients with&#xD;
      hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adrenal incidentalomas are unsuspected adrenal masses found during abdominal imaging. With&#xD;
      the widespread use of computed tomography and MRI, adrenal incidentalomas are found in&#xD;
      approximately 2% of patients. In an endocrinology setting, the majority of these masses are&#xD;
      benign adenomas of the adrenal cortex. Approximately 10% of these adenomas display little&#xD;
      excess of cortisol secretion associated to some degree of secretory autonomy but that are&#xD;
      insufficient to generate overt Cushing's syndrome (&quot;Subclinical Secreting Cortisol&#xD;
      incidentalomas&quot; or SCSI). However, hypertension and to a lesser degree obesity and impaired&#xD;
      glucose tolerance are very frequent amongst patients with SCSI. The hypothesis that the mild&#xD;
      hypercortisolism associated with SCSI is responsible for these clinical consequences is&#xD;
      substantiated by few studies describing improvement after resection of SCSI. However, these&#xD;
      studies were retrospective, uncontrolled and suffered from imprecision and numerous&#xD;
      methodological bias. Thus, whether surgery is more beneficial than medical treatment is&#xD;
      currently unknown and there is no consensus on the appropriate treatment for SCSI.&#xD;
&#xD;
      Patient selection Run-In period. Discontinuation of previous antihypertensive treatments and&#xD;
      prescription of a standardized anti-hypertensive drug regimen (SAHR). Monthly Blood Pressure&#xD;
      (BP) measurement using home BP monitoring. The duration of the Run-In periods will be ≤ 6&#xD;
      months and will end when BP will be controlled with the SAHR at two consecutive visits.&#xD;
&#xD;
      End of RI Second endocrine assessment for eligibility Randomization (Ra): 24h Ambulatory BP&#xD;
      measurement, anthropometric and metabolic evaluation. Quality of life and cognition&#xD;
      questionnaires. Randomization in 2 groups : Gr 1 Treatment group : Surgery followed by&#xD;
      intensive medical care ; Gr 2 : Control Group : intensive medical care only.&#xD;
&#xD;
      Ra + 1Mo: Surgery in Group 1 Ra + 2.5 Mo to Ra + 13 Mo: 6 weeks interval follow-up Evaluation&#xD;
      of home BP monitoring and adaptation of the SAHR. A step by step reduction of the SAHR will&#xD;
      be attempted in the two patient groups at Ra+2.5Mo. A second attempt will systematically be&#xD;
      performed in both groups at Ra+8.5 Medical evaluation of associated metabolic conditions&#xD;
      (obesity, diabetes, dyslipidemia) and adaptation of treatments Record of medical events and&#xD;
      side effects of treatments Ra + 13Mo: Final evaluation. Endocrine assessment. 24h Ambulatory&#xD;
      BP measurement, anthropometric and metabolic evaluation. Quality of life and cognition&#xD;
      questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 9, 2015</start_date>
  <completion_date type="Anticipated">November 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 9, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure value and SAHR step 12 months after inclusion</measure>
    <time_frame>12 months</time_frame>
    <description>Treatment response will defined as a reduction of at least 1 step of SAHR at the end of the study, with BP maintained within the study objectives (125-135 mm Hg systolic and 75-85 mm Hg diastolic) according to self-measurement at home.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antihypertensive treatment score and daily drug dose</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications in the two strategies.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct costs of the two strategies.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of predictive factors for the success of surgery on BP</measure>
    <time_frame>12 months</time_frame>
    <description>age, family history of hypertension, duration of hypertension, kidney function, biochemical endocrine abnormalities, urinary steroid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients requiring antihypertensive treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hours ambulatory blood pressure monitoring values</measure>
    <time_frame>At inclusion (day 0) and at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose and lipid lowering agents values</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors/markers level</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of the two therapeutic strategies with regard to cardiovascular risk factors/markers: BMI, body composition evaluated by DEXA, abdominal fat evaluated on CT-scan, fasting blood glucose and insulin, HbA1C, HOMA-IR (homeostasis model of assessment of insulin resistance) and OGTT (oral glucose tolerance test), blood lipids, pro-inflammatory adipokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with persistent diabetes, dyslipidemia and metabolic syndrome</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life</measure>
    <time_frame>At inclusion and 12 months</time_frame>
    <description>Comparison of the two therapeutic strategies with regard to quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Adrenal Incidentalomas</condition>
  <arm_group>
    <arm_group_label>Surgery followed by intensive medical care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic surgical removal of the adrenal tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive medical treatment only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standardized medical treatment of hypertension by SAHR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic surgical removal of the adrenal tumor</intervention_name>
    <arm_group_label>Surgery followed by intensive medical care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standardized medical treatment of hypertension by SAHR</intervention_name>
    <description>Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:&#xD;
step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )&#xD;
step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)&#xD;
step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg&#xD;
step 4: Add-on of Indapamide LP 1.5 mg&#xD;
step 5: Add-on of Spironolactone 25 mg&#xD;
step 6: Add-on of Bisoprolol 10 mg&#xD;
step 7: Add-on of Prazosine LP 5mg/day.</description>
    <arm_group_label>Intensive medical treatment only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≤ 80 years.&#xD;
&#xD;
          -  Incidentally discovered unilateral SCSI:&#xD;
&#xD;
               -  Adrenocortical tumor on CT (spontaneous density &lt; 20 HU and/or relative wash-out&#xD;
                  &gt; 40%, absolute wash-out &gt; 60% ) and &gt; 2 cm in size.&#xD;
&#xD;
               -  Impaired DST (cortisol &gt; 138 nmol/L or 5 µg/dL)&#xD;
&#xD;
        OR&#xD;
&#xD;
        • Impaired DST (cortisol &gt; 50 83 nmol/L or 1,8 3 µg/dL) AND one biological abnormality of&#xD;
        the corticotropic axis at study entry:&#xD;
&#xD;
          -  8 a.m. plasma ACTH &lt; 2.2 pmol/L (10 pg/ml),&#xD;
&#xD;
          -  In case of ACTH at 8 a.m. between 10 and 20 pg/mL (2.2 and 4.4 pmol/L), peak of ACTH &lt;&#xD;
             30 pg/mL (6.6 pmol/L) after a CRH test&#xD;
&#xD;
          -  midnight cortisol &gt; 150 nmol/L (5.4 µg/dL)&#xD;
&#xD;
          -  elevated late-evening salivary cortisol according to the range of the assay&#xD;
&#xD;
          -  increased 24-hour free urinary cortisol but &lt;2.0-fold the laboratory upper normal&#xD;
             limit.&#xD;
&#xD;
          -  Systolic or diastolic hypertension treated&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Systolic or diastolic hypertension (&gt; 135/85 mmHg) not treated assessed on standard&#xD;
             blood pressure self-measurement device.&#xD;
&#xD;
          -  Written informed consent signed by patient and investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 80 years.&#xD;
&#xD;
          -  Bilateral incidentaloma.&#xD;
&#xD;
          -  Incidentally adrenocortical tumor &lt; 2 cm&#xD;
&#xD;
          -  History of myocardial infarction, pulmonary edema or stroke during the previous year&#xD;
&#xD;
          -  Malignant hypertension (&gt; 175-115 mm Hg on self-measurement)&#xD;
&#xD;
          -  Beta-blocker treatment that cannot be suspended.&#xD;
&#xD;
          -  Free urinary cortisol &gt; 2.0-fold upper normal limit&#xD;
&#xD;
          -  08h00 plasma ACTH concentration &gt; 4.4 pmol/L (20 pg/ml)&#xD;
&#xD;
          -  Chronic renal insufficiency (clearance &lt; 30 mL/min)&#xD;
&#xD;
          -  Exogenous corticosteroid treatment by general or local route (inhaled, eye or ear&#xD;
             drops , ophthalmic ointment, topical skin application, ear infiltration) during the 6&#xD;
             months before the trial&#xD;
&#xD;
        OR&#xD;
&#xD;
        • Need for Corticosteroid treatment&#xD;
&#xD;
        OR&#xD;
&#xD;
        • Medication interfering with dexamethasone metabolism.(54)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Life-threatening pathology (in the short term)&#xD;
&#xD;
          -  Contra-indications to surgery&#xD;
&#xD;
          -  Lack of control of blood pressure at the end of the Run-In period&#xD;
&#xD;
          -  Dissipation of the biological endocrine criteria for SCSI at the end of the Run-In&#xD;
             period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric FRISON, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Médecine Interne, Endocrinologie et Nutrition - CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service Endocrinologie, Diabétologie, maladies métaboliques - CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <state>Aquitaine</state>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie - Niveau 18 - Caen CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <state>Basse-Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Diabétologie, Nutrition - CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <state>Haut De France</state>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinologie, Diabète et Maladies Métaboliques - CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <state>Haute-Normandie</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie et des Maladies de la Reproduction- Assistance Publique - Hôpitaux de Paris - Hôpial Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <state>ILE DE France</state>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris - Hôpital COCHIN</name>
      <address>
        <city>Paris</city>
        <state>ILE DE France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hypertension et de Médecine Vasculaire - Assistance Publique - Hôpitaux de Paris - Hôpital européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <state>ILE DE France</state>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie et Maladies Métabolique - CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrénées</state>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Diabétologie et Métabolisme - CHRU de LILLE</name>
      <address>
        <city>Lille</city>
        <state>Nord-Pas-de-Calais</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département Endocrinologie-Diabétologie -Nutrition - CHU d'ANGERS</name>
      <address>
        <city>Angers</city>
        <state>Pays De La Loire</state>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIC Endocrinologie-Nutrition - CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <state>Pays De La Loire</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Diabète et Maladies Métaboliques - Assistance publique - Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Côte d'Azur</state>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endokrinologie, Diabetes und Ernährungsmedizin, Campus Mitte, Medizinische Klinik - Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine I, Endocrine and Diabetes Uni -University Hospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S Orsola-Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adrenal Incidentaloma</keyword>
  <keyword>Subclinical Cushing's syndrome</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Cardiovascular Risk Factors</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Surgery of adrenal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocortical Adenoma</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

